Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis

Gene ◽  
2019 ◽  
Vol 692 ◽  
pp. 119-125 ◽  
Author(s):  
Linbo Chen ◽  
Dewen Lu ◽  
Keke Sun ◽  
Yuemei Xu ◽  
Pingping Hu ◽  
...  
Biomolecules ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. 519
Author(s):  
Elham Kashani ◽  
Mahrooyeh Hadizadeh ◽  
Vahid Chaleshi ◽  
Reza Mirfakhraie ◽  
Chris Young ◽  
...  

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, representing 13% of all cancers. The role of epigenetics in cancer diagnosis and prognosis is well established. MicroRNAs in particular influence numerous cancer associated processes including apoptosis, proliferation, differentiation, cell-cycle controls, migration/invasion and metabolism. MiRNAs-137 and 342 are exon- and intron-embedded, respectively, acting as tumour-suppressive microRNA via hypermethylation events. Levels of miRNAs 137 and 342 have been investigated here as potential prognostic markers for colorectal cancer patients. The methylation status of miRNA-137 and miRNA-342 was evaluated using methylation-specific (MSP) polymerase chain reaction (PCR) on freshly frozen tissue derived from 51 polyps, 8 tumours and 14 normal colon mucosa specimens. Methylation status of miRNA-137 and miRNA-342 was significantly higher in tumour lesions compared to normal adjacent mucosa. Surprisingly, the methylation frequency of miR-342 (76.3%) among colorectal cancer patients was significantly higher compared to miR-137 (18.6%). Furthermore, normal tissues, adjacent to the lesions (N-Cs), displayed no observable methylation for miRNA-137, whereas 27.2% of these N-Cs showed miRNA-342 hypermethylation. MiRNA-137 hypermethylation was significantly higher in male patients and miR-342 hypermethylation correlated with patient age. Methylation status of miRNA-137 and miRNA-342 has both diagnostic and prognostic value in CRC prediction and prevention.


Author(s):  
Chandra Agusrly ◽  
Taufik Sungkar ◽  
Gontar Alamsyah Siregar

The staging can be used as one of the prognostic factors providing a clinical picture of the patient in the future in colorectal cancer patient. In addition, carcinoembryonic antigen (CEA) as tumor markers can determine the commonly used diagnosis and prognosis of colorectal cancer. Objective: The aims study was to investigate the relationship of the staging and carcinoembryonic antigen serum levels in colorectal cancer patients. Methods. This was an analytical study with a cross-sectional design. The sample used was colorectal cancer patients at H. Adam Malik General Hospital, Medan from January 2016 to December 2018. As many as 52 subject study who met the inclusion and exclusion criteria. The Kruskal-Wallis test was used to determine relationship between staging and CEA serum levels. Results: The median value of carcinoembryonic antigen levels in Stage I, II, III, and IV group was (2.74 ng/ml vs 6.16 ng/ml vs 2.52 ng/ml, vs 26.87 ng/ml; p=0.003) respectively. Conclusion: There was relationship between staging and carcinoembryonic antigen serum levels in colorectal cancer patient


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15612-e15612
Author(s):  
Li Jingjing ◽  
Yiwen Zhang ◽  
Xu Qi ◽  
Qing Wei ◽  
Jieer Ying ◽  
...  

e15612 Background: Clinical trials suggested that solid tumors with MSI-high or dMMR are associated with responses to programmed cell death 1 inhibitors. Understanding the associations of MMR status with clinicopathological characteristics in CRC patients would help further guide clinical treatment and explore the pathogenetic mechanisms of this disease. Methods: Bioinformatics analysis was used to identify the differential expression genes between CRC patients with different MMR status. 208 resectable colorectal cancer patients, including 104 dMMR patients and 104 matched pMMR patients were retrospectively analyzed. Clinicopathological data, including age, gender, tumor location, histological subtype, tumor grade, tumor stage, regional lymph node (LNs) metastasis, American Joint Committee on Cancer (AJCC) 8th edition stage, perineural invasion, vascular invasion, number of retrieved LNs, number of metastatic LNs, systemic inflammation markers, including C-reactive protein (CRP), lactic dehydrogenase (LDH), albumin, neutrophil, monocyte, lymphocyte, platelet and survival were retrospectively reviewed. Results: Bioinformatics analysis shown chemokine-mediated signalling pathway and inflammatory response were the main differences in gene expression between dMMR and pMMR CRC patients. In all 208 CRC patients, those with dMMR were more frequently located in right side, with more mucinous adenocarcinoma, and with more grade 3 for tumor grade. Patients with dMMR had earlier AJCC stage than pMMR ones. Meanwhile, lymph nodes (LNs) metastasis was more frequently in dMMR patients compared with pMMR patients. Interestingly, CRC patients with dMMR were able to remove more regional lymph nodes during surgery, but with less metastati. Resectable CRC patients with dMMR were more likely to have higher level of neutrophil, monocyte, platelet, NLR, PLR, MLR, CAR, GPS and CRP. In CRC patients with dMMR, the patients with higher level of PLR, MLR, CAR and co-effect present had shorter OS significantly. It was interesting to note that the prognosis of high level of systemic inflammatory markers did not predict long OS in pMMR CRC patients. Conclusions: dMMR CRC has presented a comprehensively distinct systemic inflammatory microenvironment. The systemic inflammatory response can predict oncological outcomes in CRC patients with dMMR.


2018 ◽  
Vol 37 (11) ◽  
pp. 1015-1024
Author(s):  
Fabiola Müller ◽  
Marrit A. Tuinman ◽  
Ellen Stephenson ◽  
Ans Smink ◽  
Anita DeLongis ◽  
...  

2019 ◽  
Author(s):  
Julia Sánchez-Gundín ◽  
Cristina Martín-Sabroso ◽  
Ana M. Fernández-Carballido ◽  
D. Barreda-Hernández ◽  
Ana I. Torres-Suárez

Sign in / Sign up

Export Citation Format

Share Document